NCT00430365: Phase 3 - IFM2005-02 - Maintenance Therapy Using Lenalidomide in Myeloma
Updated: Sep 27, 2022
IFM2005-02
Maintenance Therapy Using Lenalidomide in Myeloma (IFM2005-02)
NCT00430365: Phase 3 - Maintenance Therapy Using Lenalidomide in Myeloma (IFM2005-02):
Maintenance treatment of myeloma.
Relevance of Maintenance Therapy Using Lenalidomide (Revimid®) After Autologous Stem Cell Transplantation Patients Under the Age Of 65. (Open, Randomised, Multi-centric Trial Versus Placebo).
Sponsor
University Hospital, Toulouse
Collaborators
Intergroupe Francophone du Myelome
ClinicalTrials.gov Identifier: NCT00430365
First Posted : February 1, 2007
Relevance of Maintenance Therapy Using Lenalidomide (Revimid®) After Autologous Stem Cell Transplantation Patients Under the Age Of 65. (Open, Randomised, Multi-centric Trial Versus Placebo).
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma
NEJM; May 2012
Belgium
France
Switzerland
Comments